How Sensitive Are Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitors for Squamous Cell Carcinoma of the Lung Harboring EGFR Gene–Sensitive Mutations?  by Zhou, Fei et al.
e19Copyright © 2013 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 9, Number 2, February 2014 Letters to the Editor
(such as clinical factors, pathologic 
features, and tumor markers).
Second, in the study by Hata 
et al.4 two patients had a point muta-
tion in exon 18 (G719X). To date, no 
final conclusion has been reached on 
the prognostic role of mutation type 
in EGFR-TKIs treatment. Several pre-
vious phase III studies only enrolled 
the patients with common EGFR 
mutations (L858R and exon 19 dele-
tions).1–3 In contrast, in the LUX-Lung 
3 study,5 L858R and exon 19 dele-
tions were defined as common EGFR 
mutations and others were defined as 
uncommon mutations. Interestingly, 
in common EGFR mutations (L858R 
and exon 19 deletions), median PFS 
was 13.6 months for afatinib (hazard 
ratio [HR], 0.47; 95% CI, 0.34–0.65; 
p=0.001) but in unselected EGFR 
mutations, median PFS was 11.1 
months for afatinib (HR, 0.58; 95% 
CI, 0.43–0.78; P=0.001). We specu-
late that the efficacy of EGFR-TKIs 
in common EGFR mutations is supe-
rior to that in uncommon mutations 
(although the numbers of uncommon 
mutations were very small in the LUX-
Lung 3 study, 26 in afatinib arm and 
11 in chemotherapy arm). However, 
Hata et al. did not mention whether 
or not the survival analysis of their 
study4 included these two patients, and 
if included, this may affect the results.
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epidermal growth factor receptor–tyro-
sine kinase inhibitors (EGFR-TKI) in 
personalized first-line treatment in non–
small-cell lung cancer patients harboring 
EGFR-sensitive mutations. However, in 
the West Japan Thoracic Oncology Group 
(WJTOG) 3405, European Tarceva ver-
sus Chemotherapy (EURTAC), and 
OPTIMAL studies, there were only one, 
one, and eight patients with squamous 
cell carcinoma (SQC) in each cohort, 
respectively.1–3 Thus, the efficacy of 
EGFR-TKIs for EGFR-mutated SQC 
needs to be further established.
In this context, we read the 
article by Hata and colleagues4 with 
great interest. We were attracted by the 
results, particularly regarding the effi-
cacy of EGFR-TKIs in EGFR-mutated 
SQC patients. However, to better under-
stand these conclusions, we believe 
some other considerations should be 
taken into account.
First, in the study by Hata et al.,4 
the median progression-free sur-
vival (PFS) (EGFR-positive versus 
 -negative) was 1.4 months (95% con-
fidence interval [CI], 0.7–5.8 months) 
versus 1.8 months (95% CI, 1.0–2.4 
months, p=0.1734) and the median 
overall survival (EGFR-positive ver-
sus -negative) was 14.6 months (95% 
CI, 2.9–undeterminable months) ver-
sus 11.0 months (95% CI, 5.7–15.7 
months, p=0.5472), respectively. 
Hence Hata et al. indicated that EGFR-
TKIs seem to be generally less effective 
in EGFR-mutated SQC than in EGFR-
mutated adenocarcinoma. However, it 
should be noted that previous clinical 
trials compared the efficacy of first-
line EGFR-TKIs versus the standard 
chemotherapy regimens in EGFR-
mutated patients,1–3 thus, we consider 
that the efficacy of chemotherapy in 
EGFR-mutated SQC patients is also 
very important (there were 14 EGFR-
mutated SQC patients receiving plati-
num doublets as first-line treatment in 
their study,4 however, the authors did 
not present the efficacy information). 
Moreover, we believe that when there 
is strong evidence to demonstrate that 
EGFR-TKIs are significantly superior 
to chemotherapy in EGFR-mutated 
SQC patients, the identification of 
SQC patients by using EGFR muta-
tion analysis will be more meaningful 
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are also positive and are associated with a 
positive response to  crizotinib treatment.3
In contrast, single green signals 
(5′) are not considered ALK FISH posi-
tive because it lacks ALK tyrosine kinase 
domain. It is likely that the reported case 
(case 2) corresponds to this situation 
rather than an asymmetric splitting of 
the 5′ probe. We have already seen simi-
lar cases in our practice and it does not 
surprise us that crizotinib therapy failed.
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To the Editor:
Several randomized phase III clini-
cal trials have revealed the pivotal role of 
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before EGFR-TKI in patients with 
minor mutations. It is more diffi-
cult to administer platinum doublets 
as second-line treatment, compared 
with EGFR-TKI. In patients with 
SQC harboring minor mutations, pri-
ority of EGFR-TKI becomes much 
lower.
The diagnostic limitations of 
small biopsies and intratumoral het-
erogeneity make definitive diagnoses 
difficult.5 Clinicians should understand 
the limitations of pathologic diagno-
sis based on small biopsies, and need 
to cooperate with pathologists to bet-
ter reach a diagnosis for individual 
patients. EGFR-TKI sensitivity in 
EGFR-mutated SQC should be judged 
by the general factors of the patient.
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Several studies in patients with 
EGFR mutations demonstrated the 
efficacy of platinum doublets; and 
the response rate (RR) and median 
 progression-free survival (PFS) were 
approximately 30% and 6 months,2 
similar to our 14 EGFR-mutated SQC 
patients receiving platinum doublets 
as first-line treatment. Compared with 
our EGFR-TKI results (RR, 25% and 
median PFS, 1.4 months),3 we would 
generally choose platinum doublets 
as first-line treatment before EGFR-
TKIs in such patients. However, we 
should ponder how many EGFR-
mutated adenocarcinoma cells are 
included in an SQC case. If the 
EGFR-mutated SQC patient is sus-
pected as harboring EGFR-mutated 
adenocarcinoma propensity per the 
following factors: female, never 
smoker, high carcinoembryonic anti-
gen, and thyroid transcription factor-1 
positive, we could try EGFR-TKI as a 
first-line treatment. Conversely, male, 
current smoker, high cytokeratin 19 
fragment, and p63 positive patients 
would be better served by platinum 
doublets. We should recognize some 
EGFR-mutated SQC include an 
incomplete sampling of adeno-SQC 
and/or poorly differentiated adeno-
carcinoma morphologically mimick-
ing SQC. Approximately one third 
of the EGFR-mutated SQC patients 
in our study obtained a PFSof lon-
ger than 6 months, and most of them 
had adenocarcinoma propensities. To 
better identify EGFR-TKI–sensitive 
SQC patients, not only EGFR muta-
tion status, but also clinical factors 
and pathologic findings should be 
taken into consideration.
Unfortunately, both of our two 
patients with a G719X point mutation 
in exon 18 did not undergo EGFR-
TKIs in our study. Sensitivities of 
 EGFR-TKIs in minor EGFR muta-
tions such as G719X seem to be less 
effective than major mutations such 
as deletional mutations in exon 19 
and a L858R point mutation in exon 
21. In patients with minor muta-
tions, the RR and PFS were shown to 
be 30% to 50% and 3 to 5 months, 
comparable to platinum doublets.4 In 
our opinion, we would choose plati-
num doublets as first-line treatment, 
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In Response:
We are thankful for the thought-
ful suggestions by Zhou et al.1 They 
raised two intriguing questions: first, 
which is better, platinum doublets 
or epidermal growth factor recep-
tor (EGFR)–tyrosine kinase inhibitor 
(TKI) as first-line treatment in squa-
mous cell carcinoma (SQC) patients 
with EGFR-sensitive mutations; and 
second, how do we treat patients with 
minor EGFR mutations?
